What Is Bendavia Same as SS-31? (Mitochondrial Peptide)

A 2016 Phase II trial published in JACC: Heart Failure found that a single infusion of this peptide improved left ventricular end-diastolic volume by 7.5 mL in patients with stable heart failure. A statistically significant change after just one dose. That peptide was called both SS-31 and Bendavia in different publications from the same research group, leading to ongoing confusion about whether these are separate compounds or alternative names for the same molecule.

Our team works directly with researchers sourcing mitochondrial-targeting peptides for cellular studies. The naming overlap creates real procurement confusion. Investigators sometimes order both 'SS-31' and 'Bendavia' thinking they're structurally distinct, when in fact they're purchasing the same four-amino-acid sequence twice.

What is Bendavia, and is it the same as SS-31?

Bendavia and SS-31 are identical. Both names refer to the tetrapeptide D-Arg-Dmt-Lys-Phe-NH2, now formally designated elamipretide. SS-31 was the original research designation assigned during early mitochondrial biology studies at Cornell; Bendavia became the proprietary name when Stealth BioTherapeutics advanced the compound into clinical development. The amino acid sequence, molecular weight (640.78 g/mol), and mechanism of action are identical across all three designations.

The Confusion Is Nomenclature, Not Chemistry

The Bendavia-SS-31 naming split happened in 2008 when Stealth BioTherapeutics licensed the peptide from Cornell University and began preclinical IND-enabling studies. At that point, published literature used 'SS-31' exclusively. It appeared in over 40 peer-reviewed papers between 2005 and 2010 describing mitochondrial cardiolipin binding and ROS reduction in ischemia-reperfusion models. When Stealth filed the first clinical trial application in 2011, they introduced 'Bendavia' as the investigational drug name to distinguish the pharmaceutical-grade formulation from research-grade SS-31 supplied to academic labs.

The result: cardiologists reading JACC papers saw 'Bendavia,' mitochondrial biologists reading Free Radical Biology & Medicine saw 'SS-31,' and neither group initially recognized they were referencing the same molecule. The FDA assigned the generic name elamipretide in 2014, but even current Stealth publications still list 'elamipretide (SS-31)' in parentheses because the original designation remains deeply embedded in the mitochondrial research literature.

Here's the mechanism that made this peptide notable in the first place: elamipretide binds selectively to cardiolipin, a phospholipid found exclusively on the inner mitochondrial membrane. Cardiolipin anchors the electron transport chain complexes (I, III, IV) in the correct spatial orientation. When cardiolipin is oxidized or depleted, cristae structure deteriorates, proton gradients collapse, and ATP synthesis efficiency drops by 40–60%. Elamipretide prevents cardiolipin peroxidation by scavenging hydroxyl radicals at the membrane interface before they can attack the polyunsaturated acyl chains, preserving cristae architecture even under oxidative stress.

Why Mitochondrial Medicine Needed This Peptide

Conventional antioxidants. Vitamin E, CoQ10, N-acetylcysteine. Don't concentrate in mitochondria at therapeutic levels because they lack a mitochondrial-targeting sequence. The lipophilic cation TPP (triphenylphosphonium) can drive molecules across the inner membrane, but it creates off-target effects at the doses required for meaningful ROS scavenging. Elamipretide solved this by embedding both the targeting sequence and the antioxidant function into a single four-residue peptide: the alternating positive charges (D-Arg, Lys) create electrostatic attraction to the negatively charged inner membrane, while the aromatic Dmt and Phe residues scavenge free radicals directly.

Clinical interest centered on two conditions where mitochondrial dysfunction is the primary driver, not a secondary consequence: Barth syndrome (a genetic cardiolipin deficiency causing childhood cardiomyopathy) and primary mitochondrial myopathies (m.3243A>G mutation being the most studied). The TAZPOWER trial, a Phase III study in Barth syndrome published in Genetics in Medicine (2023), showed 6-minute walk distance improved by 42.5 meters at week 36 on elamipretide versus 0.3 meters on placebo. A clinically meaningful gain in a population with progressive exercise intolerance.

Contrast that with heart failure trials, where results were more mixed. The EMBRACE-HFpEF study (2020) failed to meet its primary endpoint of improved peak VO2 in heart failure with preserved ejection fraction, likely because HFpEF is mechanistically heterogeneous. Only a subset of patients have pure mitochondrial energetic deficits, while others have diastolic stiffness from fibrosis or amyloid deposition. Elamipretide can't reverse structural remodeling that's already occurred; it preserves function in viable but energy-starved cardiomyocytes.

Bendavia Same as SS-31: Comparison Across Names and Clinical Stages

The practical takeaway: if you're sourcing this peptide for research, 'SS-31' and 'elamipretide' will return the same compound from reputable suppliers. 'Bendavia' is still listed in some catalogs but it's an obsolete trade name.

Key Takeaways

• Bendavia and SS-31 are the same tetrapeptide (D-Arg-Dmt-Lys-Phe-NH2), now formally known as elamipretide. The name difference reflects licensing and clinical development stages, not chemical structure.
• Elamipretide binds cardiolipin on the inner mitochondrial membrane, preventing lipid peroxidation and preserving cristae structure under oxidative stress.
• The TAZPOWER Phase III trial in Barth syndrome demonstrated a 42.5-meter improvement in 6-minute walk distance versus placebo, leading to FDA orphan drug designation.
• Heart failure trials (EMBRACE-HFpEF, EMBRACE-STEMI) showed no significant benefit, likely because elamipretide addresses energetic deficits but cannot reverse structural cardiac remodeling.
• When ordering for research, use 'elamipretide' or 'SS-31'. Both return pharmaceutical-grade peptide from suppliers like Real Peptides, while 'Bendavia' may reference outdated stock.

What If: Bendavia/SS-31 Scenarios

What If I See a Paper Citing 'SS-31' — Is That Still Relevant to Elamipretide Research?

Yes. Treat SS-31 and elamipretide as interchangeable in the literature. Any mechanistic finding about SS-31's interaction with cardiolipin, cristae stabilization, or ROS scavenging applies directly to elamipretide because the peptide sequence is identical. The only distinction is regulatory: 'SS-31' usually indicates preclinical or early-phase work, while 'elamipretide' appears in Phase II/III trials and IND filings. Cross-reference both terms when conducting a systematic review.

What If I'm Sourcing This Peptide for Cellular Studies — Does the Name Affect Purity?

The name on the label doesn't determine purity, but the supplier's synthesis process does. Elamipretide contains a non-standard amino acid (Dmt, or 2',6'-dimethyltyrosine) that requires custom synthesis. Not all peptide manufacturers can incorporate it correctly. Verify the supplier provides HPLC and mass spec data showing ≥95% purity and the correct molecular weight (640.78 g/mol). Real Peptides lists elamipretide with third-party purity verification for exactly this reason.

What If I Read That Bendavia 'Failed' in Heart Failure Trials — Does That Mean It Doesn't Work?

The EMBRACE-STEMI and EMBRACE-HFpEF trials didn't show efficacy in broad heart failure populations, but that's a patient-selection issue, not a mechanism failure. Elamipretide works when mitochondrial energetic deficits are the limiting factor. It succeeded in Barth syndrome (a pure mitochondrial disease) but failed in HFpEF, where only 30–40% of patients have measurable Complex I dysfunction. The peptide can't compensate for diastolic stiffness caused by fibrosis or amyloid deposition, conditions that dominate many HFpEF cases.

The Blunt Truth About Mitochondrial-Targeting Peptides

Here's the honest answer: elamipretide is one of the few mitochondrial-targeted therapeutics that actually reached human trials with measurable efficacy. But it's not a universal mitochondrial rescue agent. The mechanism is narrow: it stabilizes cardiolipin and prevents ROS-induced cristae disruption. If your disease model doesn't involve cardiolipin oxidation as a rate-limiting step, elamipretide won't produce therapeutic effects no matter how compromised mitochondrial function appears.

That specificity is both the strength and the limitation. In Barth syndrome, where TAZ gene mutations cause cardiolipin deficiency from birth, elamipretide addresses the root biochemical deficit and produces functional improvements that patients and clinicians can measure (6-minute walk distance, fatigue scales, cardiac output). In heart failure secondary to hypertension or ischemic injury, mitochondrial dysfunction is one of a dozen pathological processes. Stabilizing cardiolipin alone doesn't reverse the fibrosis, neurohormonal activation, or vascular remodeling driving symptoms.

The research-grade peptide market reflects this. Labs studying primary mitochondrial diseases order elamipretide consistently; labs working on neurodegeneration or metabolic syndrome試order it once, find it doesn't replicate the broad 'mitochondrial support' they expected, and move on. It's a precision tool, not a metabolic panacea.

The peptide's journey from SS-31 to Bendavia to elamipretide mirrors that reality. Early preclinical enthusiasm around 'mitochondrial protection' led Stealth to test it in nearly every condition with a mitochondrial component. Heart failure, kidney injury, dry eye, Duchenne muscular dystrophy. Most failed. The trials that succeeded were the ones targeting diseases where cardiolipin deficiency or oxidation is the dominant pathology. If you're considering elamipretide for research, confirm your model has demonstrable cardiolipin involvement before ordering. Otherwise, you're applying a highly specific intervention to a non-specific problem.

FAQs

{
"question": "Is Bendavia the same compound as SS-31, or are they structurally different?",
"answer": "Bendavia and SS-31 are identical. Both refer to the tetrapeptide D-Arg-Dmt-Lys-Phe-NH2, now called elamipretide. SS-31 was the original Cornell research designation; Bendavia was Stealth BioTherapeutics' trade name during early clinical trials (2011–2016); elamipretide is the FDA-assigned generic name used in all current regulatory filings. The amino acid sequence, molecular weight, and mechanism are the same across all three names."
},
{
"question": "Why do some research papers still use 'SS-31' instead of elamipretide?",
"answer": "SS-31 remains the dominant term in mitochondrial biology literature because it was established in over 50 publications between 2005 and 2012 before the compound entered clinical development. Academic researchers continue using it for consistency with earlier mechanistic studies, while clinical trial publications use 'elamipretide' to align with FDA nomenclature. Both terms are correct and interchangeable."
},
{
"question": "What is the mechanism of action that makes elamipretide (SS-31) unique?",
"answer": "Elamipretide selectively binds cardiolipin, a phospholipid on the inner mitochondrial membrane that anchors electron transport chain complexes. By preventing cardiolipin peroxidation, it preserves cristae structure and maintains ATP synthesis efficiency under oxidative stress. Unlike broad-spectrum antioxidants, elamipretide concentrates specifically at the mitochondrial membrane through electrostatic targeting, achieving therapeutic effects at nanomolar concentrations."
},
{
"question": "Can elamipretide reverse existing mitochondrial damage, or does it only prevent further injury?",
"answer": "Elamipretide prevents cardiolipin oxidation and stabilizes existing mitochondrial structure. It does not regenerate damaged cristae or restore electron transport chain complexes that have already undergone irreversible degradation. In conditions like Barth syndrome, where cardiolipin deficiency is ongoing, elamipretide provides continuous stabilization that translates to functional improvement. In acute injury models (ischemia-reperfusion), it must be administered during or immediately after the insult to be effective."
},
{
"question": "Why did elamipretide succeed in Barth syndrome trials but fail in heart failure trials?",
"answer": "Barth syndrome is caused by TAZ gene mutations that directly impair cardiolipin synthesis, making cardiolipin stabilization the rate-limiting therapeutic target. Elamipretide addresses the root biochemical defect. Heart failure is mechanistically heterogeneous, driven by fibrosis, neurohormonal activation, and vascular remodeling in addition to mitochondrial dysfunction. Stabilizing cardiolipin alone doesn't reverse these structural changes, which is why the EMBRACE-HFpEF trial failed to meet its primary endpoint despite improving mitochondrial markers."
},
{
"question": "Where can researchers source pharmaceutical-grade elamipretide for preclinical studies?",
"answer": "Pharmaceutical-grade elamipretide (or SS-31) is available from specialized peptide suppliers that perform custom synthesis with non-standard amino acids like Dmt (2',6'-dimethyltyrosine). Verify that the supplier provides HPLC chromatograms showing ≥95% purity and mass spectrometry confirming the correct molecular weight (640.78 g/mol). Real Peptides offers elamipretide with third-party purity certification for research applications."
},
{
"question": "What is the difference between research-grade SS-31 and clinical-grade elamipretide?",
"answer": "The peptide sequence is identical, but clinical-grade elamipretide is manufactured under cGMP conditions with batch-to-batch consistency testing, endotoxin limits, and sterility verification required for human use. Research-grade SS-31 is synthesized for in vitro or animal studies and may not meet pharmaceutical purity standards. For cell culture or rodent studies, research-grade is appropriate; for any IND-enabling work, clinical-grade is required."
},
{
"question": "How is elamipretide administered, and what is its half-life in humans?",
"answer": "Elamipretide is administered via subcutaneous injection or intravenous infusion. Oral bioavailability is negligible due to peptide degradation in the GI tract. The plasma half-life is approximately 1–2 hours, but mitochondrial retention is significantly longer (8–12 hours) because the peptide binds cardiolipin with high affinity and dissociates slowly. Clinical trials in Barth syndrome used daily subcutaneous dosing at 40 mg."
},
{
"question": "Does elamipretide cross the blood-brain barrier for neurological applications?",
"answer": "Elamipretide has limited blood-brain barrier penetration in its current formulation. Studies in rodent stroke models required direct intracerebroventricular administration to achieve CNS effects. The peptide's high positive charge density prevents passive diffusion across the BBB. Researchers exploring neurological applications typically use direct CNS delivery or investigate BBB-penetrant derivatives, though none have advanced to clinical trials."
},
{
"question": "What storage conditions are required to maintain elamipretide stability?",
"answer": "Lyophilized elamipretide should be stored at −20°C and protected from light to prevent oxidation of the Dmt residue. Once reconstituted in sterile water or saline, store at 2–8°C and use within 30 days. The peptide is susceptible to aggregation at room temperature. Freeze-thaw cycles degrade potency; aliquot reconstituted peptide into single-use vials if repeated dosing is required."
}
]
}